By: Edward T. F. Wei PhD
Such goals include: • achieving early recognition and intervention with nurses with a substance use disorder • ensuring patient safety while providing the nurse an opportunity to symptoms kidney cancer trusted 25 mg meclizine get into treatment and recovery • assisting the nurse in maintaining his/her license • assisting the nurse with the return-to-work process Alternative to treatment xerosis discount meclizine 25 mg without prescription discipline programs make themselves visible and available to medicine prices best order for meclizine nurse supervisors and as a result have a constant communication that regularly includes the supervisors in the monitoring of a nurse with a substance use disorder (Quinlan treatment atrial fibrillation discount generic meclizine canada, 2003) symptoms your having a boy discount meclizine amex. This suggests that organized education for professionals who serve as work-site monitors is important to ensure consistent reporting to boards and for effective monitoring of nurses with a substance use disorder who return to practice. In some situations, workplace monitors and supervisors are the same person and in others a separate point of accountability is named. Return-to-work contracts must require the supervisor and often even co-workers be involved in some way in the monitoring of the nurse with substance use disorder (Griffth, 1999). Contracts must specifcally require the nurse with a substance use disorder to notify employers of their participation in the monitoring program and the requirements of the program (Lowell and Massey, 1997). The supervisor and work-site monitor must be licensed to practice nursing, the license must be unencumbered and they can not be a current participant in any alternative program in order to avoid conficts of interest that could impede the ability to objectively monitor the nurse. The supervisor and work-site monitor must have close communications with the alternative program. The supervisor and work-site monitor must be provided with any work restrictions that have been imposed upon the nurse by the program. One such restriction may be any access to narcotics for a minimum of six to 12 months. In areas where there is high volume procurement such as intensive care units, operating rooms, anesthesia and emergency departments, care must be taken to ensure proper documentation. It has even been suggested that nurses in higher risk practice settings such as these consider using naltrexone as adjunctive therapy if the drug of choice is an opiate (Quinlan, 2003). Health care facilities are encouraged to develop an action plan to diminish the likelihood of abuse of prescription drugs (Drake, Dyer, & Holzheimer, 1997). Components of the action plan can include: • updating the narcotics policy to include who has access to controlled substances • developing a policy for dispensing take-home medications • conducting random audits of narcotics • urging the pharmacy to conduct independent and random audits of narcotics the monitoring program may also require the employer to contact the program to verify the nurse employee’s participation in the program. Many require the supervisor to fll out a supervisor agreement form that is signed by the direct supervisor prior to the nurse participant beginning or resuming a new or existing position. The supervisor needs to have face-to-face observation of the nurse in order to assess and document practice and behavior as well as to support recovery (Smith & Hughes, 1996). The supervisor or work-site monitor must be in a position to observe and report workplace performance and behavior in order to include the time and attendance, relationships with colleagues, the appearance and compliance with work conditions. The supervisor or work-site monitor and the monitoring program coordinator must also have regular contact about the recovering nurse (Clark & Farnsworth, 2006). For example, the employer must submit work performance evaluations of the nurse with a substance use disorder to the monitoring program on a regular basis and agree to notify the monitoring program immediately of any concerns about the nurse’s practice, behavior and recovery. Others suggest the supervisor schedule monthly check-in meetings with the nurse for the purpose of addressing any concerns from either party. These meetings must be documented and made available to the monitoring program upon demand. Some programs even go so far as to require the potential employer and designated supervisor to be involved in a conference call to determine whether the nurse participant may work at a particular job. However, the more contact and open communication there is, the better it is for all concerned. A supervisor or work-site monitor agreement with the participant can include the following minimum elements: • expectations for the nurse participant • instructions for any supervisory changes • education on the completion and submissions for performance report forms • procedures for communication with the monitoring program if there is suspicion of diversion, on-the-job use or work performance problems • process to be followed if the recovering nurse is unable to leave work for urine collections Monitoring programs must conduct quality assurance activities on a regular basis. Many programs already conduct an employer survey in order to maintain and assure continued quality service for program participants and to improve their delivery of service. This is also a very good way to obtain feedback from supervisors about the program. Return-to-Work Guidelines 137 the monitoring programs must then do what they can to maintain a strong presence within the nursing community. It is vital that there is open communication between the nurse participant’s supervisor and the monitoring coordinator. They must always provide information about their program to nursing management and directors and to any participant supervisor and work-site monitors. The monitoring program can help the manager by doing the following: • provide education and training about the recognition of unsafe practice and how to intervene appropriately • assist in the development of policies that are fair and consistent including the issue of ftness for duty and back-to-work parameters • assist in the coordination of back-to-work agreements • facilitate the transition of a nurse back into the workplace, including groups with coworkers with the participant’s consent • facilitate open communication between the nurse participant’s supervisor and the monitoring coordinator Procedures for Receiving Updates from the Monitoring Program Upon enrollment in an alternative program the nurse enrollees must be required to sign a consent form that enables the program monitor and other program personnel to speak with the participant’s employer. The purpose of the release is so that the program coordinator can communicate with the employer about the nurse’s recovery. Communication is essential for the nurse’s successful participation and completion of the program and for their return to practice in a manner that is conducive to both the nurse’s recovery and safe patient care. The participant’s supervisor and work-site monitor must be educated about the signs of relapse and must report any concerns about relapse behaviors or identifed relapses to the alternative program. Return to School Rather than the Workplace After completing a treatment program some nurses decide to go back to school rather than re-enter the work force. If the nurse is taking any clinical courses, the dean or director of the nursing program must be notifed of the nurse’s participation in a monitoring program (Anderson, 1994). The dean or director must identify specifc faculty who can serve as monitors to assist the nurse in recovery. Uncovering the secret: Giving voice to the experiences of nurses who misuse substances. Substance use, symptom, and employment outcomes of persons with a workplace mandate for substance use disorder treatment. Monitoring the level of Tcompliance of the nurse with the contractual agreement and prescribed treatment program is essential in order to assure patient or client safety and that the nurse is competent to practice. Once the nurse has signed the alternative program stipulated agreement or contract the alternative program staff will begin to monitor the participant nurse’s compliance with contract terms. This is accomplished by addressing each point of the contract to assure compliance. Monitoring aids recovering nurses by helping them regain employment and providing a process to evaluate recovery and rehabilitation. Monitoring may also provide objective data that helps to dispel undeserved accusations and can also identify behaviors that may lead to relapse. Mechanisms must be in place to identify and quickly respond to noncompliance by the participant with any of the terms in the stipulated agreement. An important part of monitoring is the completion and reporting of pertinent alternative program information. The reports provide an accounting of compliance with recovery plans and monitoring of random drug and alcohol testing. Recommendations for modifcation of the recovery plan are made based on factors such as compliance, recovery status and the nurse’s progress in the alternative program. The alternative program utilizes several methods and sources to monitor the progress of participant nurses. These include: • reports from treatment professionals • aftercare or continuing-care reports • individual counselor or psychotherapist reports • meeting attendance for 12-step programs and alternatives • work-site monitor reports • medical care and medication reports • drug testing • professional support group attendance • self-reports 140 Chapter Twelve Relocation out of state is not encouraged while participating in a licensure alternative program. However, if a participant nurse’s circumstances require that he/she relocate out of state while participating in the alternative program, the individual must be required (as provided within the alternative program contract) to maintain compliance with the terms of contact with the alternative program regardless of their state of residence. Additionally, they must obtain written permission from the alternative program before seeking employment or licensure in another state and obtain written permission from the alternative program in that state or if there is no alternative program, the board of nursing. Alternative program contracts must include a requirement for compliance with all terms and conditions regardless of employment or residential status. If a participant nurse decides to relocate out of state and does not inform the current alternative program, the new alternative program or the board of nursing in the new state, then the nurse will be considered to be in noncompliance with their original alternative program contract and referred to the licensing board for appropriate disciplinary action. One of the controversies surrounding alternative programs is that the participant’s status in the program is not known to other states where the person may hold licensure or may be seeking to become licensed in an effort to embark on a geographical cure for his/her licensure or practice limitations. Although not currently in place at this time, it is recommended that a national database for reporting of alternative program participation be developed and that program participants be entered into the national database. Accessing information from this database would not be used for disciplinary or other public purposes in any other state or territory as long as the participant remains in full compliance with the terms and conditions of his/her participation. This database could be used for verifying information related to licensure endorsements and persons actively licensed to practice in any given state or territory. Relapse and Program Noncompliance Relapse is always possible with nurses suffering from a substance use disorder because addiction is a chronic and incurable but treatable brain disease. Controversy surrounds the issue of relapse and the specifcs of what constitutes a relapse. Relapse can be defned as a discreet event that occurs simultaneously to the resumption of drug use or as a process that occurs over time (Smith, 1992). Relapse is a term that is often used to describe the return of signs and symptoms of a disease after an apparent period of recovery. In a substance use disorder a relapse may be defned as the recurrence of alcoholor drug-dependent behavior in an individual who has previously achieved and maintained abstinence for a period of time beyond detoxifcation. Relapse is also the movement away from recovery and is a progressive process that is marked by defnite, predictable and progressive warning signs. Gorski, a wellknown expert in recovery and relapse prevention defnes relapse as a process with 10 distinct phases and recognizable warning signs (Gorski & Miller, 1986, Gorski, 2007). The fnal phase is marked by the actual return to use by the addict of alcohol or other drugs. Recognizing and responding to the relapse warning signs are an effective means of preventing return to substance use. The alteration of thought processes, judgment and emotional reactions precede the resumption of use. If the relapse process is not halted it leads to a break in abstinence and a renewed drug or alcohol use. Studies refect that health care and other professionals who are subject to a monitoring agreement with signifcant consequences for non-compliance have a lower relapse rate than the Monitoring and Compliance 141 general population (McLellan, Skipper, Campbell, & DuPont, 2008; DuPont, McLellan, White, Merlo, & Gold, 2009; Knight, Sanchez, Sherritt, Bresnahan, & Fromson, 2007). Relapse occurs more frequently during the frst 12 months after entry into treatment but the prognosis improves the longer a person is able to maintain continuous recovery from substance use. Therefore, measures that are put into place to prevent, deter and to detect relapse must be intensifed during the frst 12 months of entry in the alternative program and can then be tapered based upon compliance and treatment recommendations. If the participants are enrolled in a state board authorized alternative program the indicators of an impending relapse or actual relapse often manifest in noncompliance by the participant with the terms of his/her alternative program’s stipulated agreement. Common signs of an impending relapse include the following: • lack of or a decreased participation in an ongoing recovery program including a 12-step program and a lack of a sponsor relationship • failing to comply with treatment recommendations • lack of honesty regarding substance use and misuse history • employment diffculties • relationship diffculties • unstable emotional status • lack of a sober support system and a return to socializing with prior using associates • failing to comply with alternative to discipline contract requirements • late or missing monitoring reports • missed drug screens • dilute specimens • altered or substituted specimens • positive drug screens the actual drug use can be considered one of the later aspects of the relapse dynamic and for the purposes of this model any use of unauthorized drugs or alcohol is considered a relapse. For these guidelines, two relapses are considered grounds for terminating the participant nurse from the alternative program and referring the nurse to the board for determination of appropriate licensure action. In any relapse situation the nurse would be referred to treatment professionals with an expertise in substance use disorder for further evaluation and treatment determination. Until determined as safe to return to nursing practice, a participant who has relapsed must also be immediately removed from nursing practice. Drug and Alcohol Testing Random drug testing is used as a preventive tool and a detection tool for unauthorized drug or alcohol use in the monitoring of participants with a substance use disorder. Urine screening is generally viewed as the preferred method for assessing substance use and may be supplemented with hair testing for some drugs to assess for drug use over long periods. A positive drug testing does not provide information about the levels of impairment but only that a drug or substance was used within the detection period and represents a signifcant breach of the alternative program contract. During periods of increased vulnerability to relapse, including the frst 12 months of monitored compliance with treatment and alternative program requirements, random drug screening must be done at minimum of twice a month.
Technique to symptoms 7dp5dt order meclizine pills in toronto measure circumference of upper limb: Ensure the limb is supported and in a straight position treatment goals for anxiety purchase meclizine 25 mg mastercard. These should be of the appropriate class and size medications management order meclizine online from canada, and a choice of fabrics and colours should be available medicine ok to take during pregnancy discount 25mg meclizine amex. It consists of light treatment 197 107 blood pressure cheap meclizine 25 mg free shipping, rhythmical strokes performed in the direction of normal lymphatic flow. Usually, it is performed for 45-60 minutes, 4 days a week for 2-4 weeks (acute phase of treatment) (Chiefetz and Hanley, 2010). This is a precise and accurate procedure using specific bandages and interfacing materials that provide external support to the skin. The gradient compressive forces push the lymphatic fluid from the interstitium into the lymph vessels increasing lymph reabsorption and stimulating lymphatic transport. In the acute phase (0-5 days) short-stretch bandages are used to reduce limb volume. Their efficiency is increased when exercises are done in conjunction due to dual-action of muscle pump and compression. Once limb volume is reduced substantially, patient is fitted for a compression garment to maintain the achieved volume. Exercise should consist of both range of motion/flexibility and strengthening and should be specific to each individual. Options include direct anatomic plane movements, scapular plane movements, or functional and combined movements. Wear gloves when doing duties, shave with electric razor, treat cuts with antiseptic lotion. Chou et al, (2012) carried out a single case study on a patient with unilateral secondary malignant breast – cancer lymphoedema and found that kinesio taping could be another choice for contraindicating pressure therapy patients instead of compressive bandaging, however it should not replace it. Furthermore, 55 Tsai et al, 2009 found that there was no significant difference between kinesio taping and bandaging for the treatment of cancer-related lymphoedema. The network is always present in the axilla and extends along the medial face of the ipsilateral arm, frequently below the cubital cavity and occasionally until the base of the thumb. Altogether 56 out of 116 patients who underwent axillary lymph-node dissection were found to have axillary web syndrome (incidence of 48. It is unrelated to the number of lymph nodes compromised or with the stage of the illness. The management included manual therapy, mostly using soft tissue treatment techniques, combined with education and advice. Pre-morbid range of movement was achieved within 11 treatments, spread over 3 weeks and after 16 weeks the patient experienced no pain. Furthermore, the patient returned to full-time employment after the seventh treatment by a physiotherapist. This results in fibrosis of the vasa nervorum (small arteries supplying blood to peripheral nerves) (Ahmad et al, 1999). Radiation-induced brachial plexopathy can occur when radiotherapy is directed at the chest, axillary region, thoracic outlet, or neck. The radiation dose, treatment technique, and concomitant use of chemotherapy all demonstrate significant association with the development of radiation injury to the brachial plexus (Bajrovic et al, 2004). One third of patients deteriorate rapidly and exhibit significant weakness, lymphoedema, and pain (Johansson et al, 2002). Signs and Symptoms fi Numbness fi Paraesthesia fi Dysesthesia fi Swelling and weakness of the arm fi Motor deficits of the ipsilateral upper extremity On Examination fi Neurologic findings in the C5-C6 myotomes and dermatomes, as well as diminished deep tendon reflexes supplied by C5-C6. Fatigue has been noted to decrease in the first 2 weeks after localized treatment for breast cancer but then to increase as radiation therapy persists into week 4. Administration of chemotherapy and radiotherapy for malignancy causes a specific fatigue syndrome. When specific causes cannot be identified, pharmacological and nonpharmacological treatment should still be carried out. Pharmacological intervention fi Exclude treatable causes fi Anaemia: Erythropoietin, Darbopoietin Both stimulate red blood cell production and are prescribed to improve anaemia in patients receiving chemotherapy. A meta-analysis of 10 studies (n = 2226 patients) evaluating erythropoietin in anaemic cancer patients undergoing chemotherapy indicated that erythropoietin was superior to placebo (Minton et al, 2008). Fatigue severity and measures of quality of life were significantly improved following 1 month of treatment with modafinil (Carroll et al, 2007). Non-pharmacological Management Exercise Education Nonpharmacological Energy Conservation Management Cognitive Behavourial Therapy Stress Management Figure 9. Three showed no effect or failed to achieve statistical significance (Schmitz et al, 2010). Patients should also be educated if they experience fatigue, it may be a side-effect of the treatment and not automatically a sign that the treatment in not successful or that the disease is evolving. It encompasses a common sense approach that helps patients to prioritize and pace activities, and to delegate less essential activities if they are experiencing moderate-to-severe fatigue. A useful plan is to maintain a daily and weekly diary that allows the patient to ascertain peak energy periods. Goedendorp et al Psychosocial interventions (education, 7 of 27 studies reviewed (2009) self-care, coping techniques, and showed a significant (Cochrane Review) learned activity management) reduction in fatigue Kangas et al (2009) Psychosocial interventions: restorative 119 studies. Identifying for each individual what has been helpful in managing stress prior to their diagnosis may help 64 the patient recognise what option to explore first in dealing with his or her emotions regarding the malignancy. Time spent fatigue both during one component bias) low-unclear risk (2012) of cancer-Participants may specific exercise training and exercising and after treatment of a of bias Cochrane related have been actively programme flexibility 3. The management -Blinding of outcome Review fatigue in receiving prescribed) or an exercises. Quality of life on fatigue were fatigue that may bias) high risk of bias -56 studies term follow-up treatment 5. Anxiety and observed include a -Selective reporting included (28 or palliative care. Depression specifically for range of other (reporting bias) low risk breast cancer 6. Effects of exercise on fatigue in cancer patients 66 5) Pain Chronic pain after cancer surgery may occur in up to 50% of patients. Risk factors include: 1) Young age 2) Chemotherapy 3) Radiotherapy 4) Poor post-operative pain control 5) Certain surgical factors. The neurophysiology of cancer pain is complex: it involves inflammatory, neuropathic, ischemic and compression mechanisms at multiple sites. Knowledge of these mechanisms and the ability to decide whether a pain is nocioceptive, neuropathic, and visceral or a combination of all three will lead to best practice in pain management. Acute pain; brief, intense, and arises suddenly, limits activities almost immediately. Medication is prescribed as needed for a short period of time until the episodes of pain subside. It can be an uncomfortable ache that is always there, or a much more intense feeling of physical distress or suffering that makes it impossible to focus on anything else. Pain Relief For Breast Cancer Pain fi Non-narcotic Analgesics (nonopoids) fi Nerve Blocking Strategies fi Narcotic Analgesics (opoids) fi Nerve Stimulation fi Coanalgesics fi Physiotherapy fi Topical Analgesics Role of Physiotherapy fi Strategies for preventing and treating lymphoedema (see lymphoedema section) fi Manual stretching and soft tissue massage fi Information about exercise programs designed to build strength and range of motion. Consequences of neuropathy can be severe for patients with cancer and may result in reduced quality of life, disability, and potentially shorter survival. Small sensory fibres are affected early and most frequently by chemotherapeutic agents. Motor nerves are generally less frequently or seriously affected by neurotoxic chemotherapy. Motor nerves that have survived a chemotherapeutic insult have the capacity for distal sprouting and reinnervation of muscle fibres that have lost their innervation (Stubblefield et al, 2009). Chemotherapeutic drugs and anticancer biologics frequently reported as associated with symptomatic neuropathy. Drug Clinical Manifestation Recovery Cisplatin Symmetrical painful parenthesis or Partial, symptoms may Carboplatin numbness in a stocking-glove progress for months Oxaliplatin distribution, sensory ataxia with gait Oxaliplatin: Resolution in 3 dysfunction months, may persist longer Oxaliplatin Cold-induced painful dysesthesia Resolution within a week Vincristine, Symmetrical tingling parenthesis, Resolution usually within vinblastine, loss of ankle stretch reflexes, 3 months, may persist for vinorelbine, vindesine constipation, occasional weakness, vincristine gait dysfunction Paclitaxel Symmetrical painful parenthesis or Docetaxel numbness in stocking-glove Abraxane distribution, decreased vibration or proprioception, occasionally weakness, sensory ataxia, and gait dysfunction Bortezomib Painful parenthesis, burning Resolution usually within 3 sensation, occasional w weakness, months, may persist sensory ataxia, and gait dysfunction. Rare autonomic dysfunction including orthostatic hypotension Xabepilone Painful parenthesis, burning Resolution in 4–6 weeks sensation Thalidomide Symmetrical tingling or numbness, May persist for over 1 year pain. The assessment methods available include clinical evaluation (grading systems), objective testing, and patient questionnaires. Physical examination should describe clinical features of the neuropathy, such as sensory abnormalities, deep tendon reflex dysfunction, motor weakness, pain characteristics, autonomic symptoms, and most importantly, functional impairment. Sensory Symptom Management: As with pain medications, most evidence supporting neurostimulation came from studies on diabetic or other types of neuropathy. However, it is an invasive technique that includes the risks and costs of surgery. Evidence for acupuncture Article Intervention Outcome Donald et al (2011) six weekly acupuncture 82% of patients reported an improvement in sessions symptoms. Clinical trial Some patients also reported a reduction in analgesic use and improved sleeping patterns. Balance Rehabilitation: Gait training and lower limb resistance training help significantly improve balance in diabetic patients compared with a control exercise regimen (Richardson et al, 2001). Assistive Devices: Assistive devices including canes, walkers, wheelchairs, and ankle-foot orthoses may also be provided if required. Compression caused by: fi Obstruction fi Invasion fi Thrombosis fi Or fibrosis of the vessel Lung cancer accounts for 85% of all incidences, malignant lymphomas of non-Hodgkin’s origin are the second main cause, other primary mediastinal tumours like thymoma or germ cell tumours make up <2% of occurrences. Signs & Symptoms fi Neck and Facial Swelling fi Hoarseness (especially around the eyes) fi Headaches fi Dyspnoea fi Nasal congestion fi Cough fi Epistaxis fi Head Fullness and Pressure fi Hemoptysis Sensation fi Dizziness fi Proptosis fi Dysphagia fi Stridor fi Arm Oedema fi Venous Distension in neck and fi Syncope thorax *Symptoms often get worse leaning forward or lying down. Also can be used to show location of obstruction and help as a guide for fine needle aspiration biopsy. Causes fi Obstruction of lymphatic drainage fi Excess fluid secretion from tumour nodules on pericardial surfaces Differential Diagnosis of Pericardial Effusion fi Non-malignant. Treatment Options fi Pericardiocentesis plus sclerosing agents like bleomycin or tetracycline fi the creation of a pericardial window fi Complete pericardial stripping fi Systematic chemotherapy 3) Malignant Spinal Cord Compression Compression is caused by extradural metastases from tumours involving the spine. Bone metastases of thoracic (70%), lumbar (20%) or cervical (10%) regions may cause a cord injury. It presents in 5-10% of all cancer patients throughout the course of their disease. Only 10% unable to walk pre diagnosis will recover the ability to mobilise post treatment Signs & Symptoms fi Localised back pain o May increase overnight o Does not improve with common analgesics o Worsens with recumberance or with manoeuvres o Worsens with increased pressure. Severe hypercalcaemia (>13 mg/dl) is linked to a short survival time of several weeks to a few months. Causes fi Bone metastases due to increased release of calcium from bone as a result of osteoclastic activity fi Increased parathyroid hormone-related protein production fi Calcitrol secretion Signs & Symptoms (Serum calcium levels >2. The tumour mass plus surrounding oedema may produce hydrocephalus and as the mass increases, various herniation syndromes may start. However, less than 22% of cancer survivors are physically active and breast cancer survivors have the lowest rate of physical activity of all cancer survivors (Courneya et al 2008). Precautions and contraindications for exercise in breast cancer patients Precautions Contraindications Pts with severe anaemiadelay exercise until improved. Swimming pools – avoid during radiotherapy Pulse at rest >100 beats per minute Severe fatigue – do 10 mins stretching daily Temperature >38°C; respiration frequency >20 per minute Peripheral neuropathy/ataxia – may benefit more from Infections requiring treatment with antibiotics stationary bike than treadmill 9 Fracture risk following hormonal therapy or patients with B thrombocytes <50fi10 /l (platelets levels) osteoporosis or bony metastasesavoid high impact activity 81 9 Individuals with cardiac conditions will require B leucocytes <1. This will direct assessment, treatment plan, education needs and goal setting, as well as giving you an idea of the patient’s motivation level. Studies Jones et al, 2004 n=450 Physical Mutrie et al, 2007 n=177 Mutrie et al, 2012 Activity Schneider et al, 2007 n=113 Outcome Exercise, especially a combination of resistance and aerobic can improve physical activity in breast cancer patients during treatment and this can be maintained at a 5 year follow up.
He also serves on the Board of Directors of the Association for the Accreditation of Human Research Protection Programs medications that cause weight loss discount 25mg meclizine with mastercard. He has pioneered the field of genome cell biology by developing live-cell microscopy approaches to medications kidney failure cheap meclizine 25mg fast delivery study the nuclear organization of the genome and gene expression in intact cells medications zyprexa best 25mg meclizine, and his laboratory aims to symptoms your dog is sick buy generic meclizine from india apply this knowledge to medications ending in pam purchase meclizine the development of novel diagnostic and therapeutic strategies for cancer and aging. Dr Misteli has received numerous awards for his work, and currently serves as Editor-in-Chief of the Journal of Cell Biology and of Current Opinion in Cell Biology. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease 88 Sean J. Morrison, PhD, is the Director of the Children’s Research Institute and the Mary McDermott Cook Chair in Pediatric Genetics at the University of Texas Southwestern Medical Center as well as an Investigator of the Howard Hughes Medical Institute. The Morrison laboratory is investigating the mechanisms that regulate stem cell function in the nervous and hematopoietic systems and the ways in which these mechanisms are hijacked by cancer cells to enable neoplastic proliferation and metastasis. The Morrison laboratory is particularly interested in the mechanisms that regulate stem cell self-renewal, stem cell aging, and the role these mechanisms play in cancer. Parallel studies of these mechanisms in two tissues reveals the extent to which different types of stem cells and cancer cells depend upon similar mechanisms to regulate their function. The Morrison laboratory has discovered a number of critical mechanisms that distinguish stem cell self-renewal from the proliferation of restricted progenitors. They have shown that stem cell self-renewal is regulated by networks of proto-oncogenes and tumor suppressors and that the balance between proto-oncogenic and tumor suppressor signals changes with age. This likely explains why the mutation spectrum changes with age in cancer patients, as different mechanisms become competent to hyper-activate self-renewal pathways in patients at different ages. The Morrison laboratory has further shown that in some cancers many tumor cells are capable of driving disease growth and progression while other cancers are driven by minority subpopulations of cancer cells that adopt “stem cell” characteristics. These insights into the cellular and molecular mechanisms of self-renewal have suggested new approaches for promoting normal tissue regeneration and cancer treatment. Morrison was at the University of Michigan where he Directed their Center for Stem Cell Biology. Morrison moved to the University of Texas Southwestern Medical Center where he is the founding Director of the new Children’s Research Institute. Morrison has also been active in public policy issues surrounding stem cell research. For example, he has twice testified before Congress and was a leader in the successful “Proposal 2” campaign to protect stem cell research in Michigan’s state constitution. Nichols is a professor of anesthesiology/critical care medicine and pediatrics and the Mary Wallace Stanton Professor of Education. Since joining the School of Medicine faculty in 1984, he has held numerous leadership posts in both the Department of Anesthesiology and Critical Care Medicine and school-wide. Nichols oversees undergraduate, graduate, residency, postdoctoral and continuing medical education programs, as well as the Welch Medical Library. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease fifi guidelines; restructure graduate medical education; oversee the design of a new $50 million medical education building; and enhance diversity throughout Johns Hopkins Medicine. Nichols was associate director of the residency education program in the Department of Anesthesiology and Critical Care Medicine. Nichols became a full professor of anesthesiology/critical care medicine and pediatrics in 1998 and became the recipient of the Mary Wallace Stanton Professorship for Education in 2005. He has written more than 80 professional journal articles and abstracts, held 17 guest professorships, headed more than 20 symposia and delivered more than 115 guest lectures. He also has been editor in chief of the leading textbooks in pediatric critical care medicine and edited Rogers Textbook of Pediatric Intensive Care and Critical Heart Disease in Infants and Children. Maynard Olson is Professor Emeritus of Medicine and Genome Sciences, at the University of Washington. His research interests focus on studies of natural genetic variation in both bacteria and humans. This research involves activities in human genetics, genomics, molecular genetics, analytical biochemistry, and computational biology. Olson was involved in shaping scientific policy toward the Human Genome Project, serving on the National Research Council Committee on Mapping and Sequencing the Human Genome, the Program Advisory Committee of the National Center for Human Genome Research Institute. In recognition of his research in genetics and genomics, he received the Genetics Society of America Medal in 1992, the City of Medicine Award in 2000, the Gairdner International Award in 2002, and the Gruber Prize in Genetics in 2007. Charmaine Royal is an Associate Research Professor in the Institute for Genome Sciences & Policy and the Department of African and African American Studies at Duke University. She subsequently completed her postdoctoral training in the Bioethics and Special Populations Research Program at the National Human Genome Research Institute of the National Institutes of Health, and in the Division of Epidemiology and Behavioral Medicine at the Howard University Cancer Center. Royal was Assistant Professor of Pediatrics and Director of the GenEthics Unit in the National Human Genome Center at Howard University. She serves on the: Bioethics Advisory Committee of the March of Dimes Foundation; Social Issues Committee of the American Society of Human Genetics; Editorial Board of the American Journal of Bioethics; and various other professional Committees and boards. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease 90 ethnicity, and identity. Her specific interests include genetic variation and the (re)conceptualization of race, use of race and ancestry in research and clinical practice, geneenvironment interactions in health and health disparities, genetic ancestry inference, involvement of historically marginalized and underrepresented groups in genetic and genomic research, and genomics and global health. She has taught, presented, published, and received funding in these and other related areas. A key objective of her research program is to advance a more holistic and ethical approach to understanding and improving human health and well-being through increased integration of genetic and genomic research with behavioral, social science, and humanities research. Yamamoto’s research is focused on signaling and transcriptional regulation by intracellular receptors, which mediate the actions of several classes of essential hormones and cellular signals; he uses both mechanistic and systems approaches to pursue these problems in pure molecules, cells and whole organisms. Yamamoto was a founding editor of Molecular Biology of the Cell, and serves on numerous editorial boards and scientific advisory boards, and national Committees focused on public and scientific policy, public understanding and support of biological research, and science education; he chairs the Coalition for the Life Sciences (formerly the Joint Steering Committee for Public Policy) and for the National Academy of Sciences, he chairs the Board on Life Sciences. Yamamoto was elected as a member of the American Academy of Arts and Sciences in 1988, the National Academy of Sciences in 1989, the Institute of Medicine in 2003, and as a fellow of the American Association for the Advancement of Sciences in 2002. Hook-Barnard is a program officer with the Board on Life Sciences of the National Research Council. She came to the National Academies from the National Institutes of Health where she was a Postdoctoral Research Fellow from 2003 to 2008. Her graduate research examined translational regulation and ribosome binding in Escherichia coli. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease fifi she contributes to projects in a variety of topic areas. Much of her current work is related to issues of molecular biology, microbiology, biosecurity and genomics. She was study director for the 2010 report Sequence-Based Classification of Select Agents: A Brighter Line, and continues to direct the U. How would a New Taxonomy of human disease enable more cost effective and rapid development of new, effective and safe drugs in the pharma/biotech settingfi How would a New Taxonomy of human disease promote integration of clinical and research cultures in the pharma/biotech industryfi How would a New Taxonomy of human disease promote public/private partnerships between industry and academiafi What are key factors that would limit the implementation of a New Taxonomy of human disease in the pharma/biotech settingfi Such studies involve testing hundreds of thousands of genetic variants called single nucleotide polymorphisms throughout the genome in people with and without a condition of interest. In addition, the consortium includes a focus on social and ethical issues such as privacy, confidentiality, and interactions with the broader community. Data Sharing Guiding Principles: All data sharing will adhere to 1) the terms of consent agreed to by research participants; 2) applicable laws and regulations, and; 3) the principle that individual sites within the network have final authority regarding whether their site’s data will be used or shared, on a per-project basis. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease 100 administered by the National Institutes of Health. In addition each Member agrees to report in writing to the other Members any use or disclosure of any portion of the data of which it becomes aware that is not permitted by this Agreement including disclosures that are required by law. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease 101 Appendix E: Glossary Biobank – A bank of biological specimens for biomedical research. Biomarker: a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Because of its location, the gene is suspected of causing the disease or other phenotype. Clinical utility the ability of a screening or diagnostic test to prevent or ameliorate adverse health outcomes such as mortality, morbidity, or disability through the adoption of efficacious treatments conditioned on test results (Khoury 2003). The polymer that encodes genetic material and therefore the structures of proteins and many animal traits. EpigenomeThe epigenome consists of chemical compounds that modify, or mark, the genome in a way that tells it what to do, where to do it, and when to do it. Exposome characterization of both exogenous and endogenous exposures that can have differential effects at various stages during a person’s lifetime (Wild 2005; Rappaport 2011). Gel Electrophoresis: electrophoresis in which molecules (as proteins and nucleic acids) migrate through a gel and especially a polyacrylamide gel and separate into bands according to size (Merriam-Webster 2007). Genbank –The GenBank sequence database is an annotated collection of all publicly available nucleotide sequences and their protein translations (Mizrachi 2002). Gene-environment interactions an influence on the expression of a trait that results from the interplay between genes and the environment. Some traits are strongly influenced by genes, while other traits are strongly influenced by the environment. Gene expression is the process by which the information encoded in a gene is used to direct the assembly of a protein molecule. Gene-expression profile Gene expression profiling is the measurement of the activity of thousands of genes at once, to create a global picture of cellular function. These profiles can, for example, distinguish between cells that are actively dividing, or show how the cells react to a particular treatment. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease 103 mutation. Examples include the sickle cell trait, the Rh factor, and the blood groups (Mosby 2009). Genetic privacy the protection of genetic information about an individual, family, or population group, from unauthorized disclosure (Kahn and Ninomiya 2010). This can either refer to known alleles (or types) of a single gene or to collections of genes. For example, some lung cancers have a mutant Egf receptor genotype while other lung cancers have a wild-type (or normal) Egf receptor genotype. Heterozygous refers to having inherited different forms of a particular gene from each parent. Histology the science dealing with the microscopic identification of cells and tissue (Mosby 2009). It is used primarily for statistical purposes in the classification of morbidity and mortality data. Longitudinal study A research study that collects repeated observations of the same items over a long period of time. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease 104 Metabolic profiling – Identifying the types and amounts of known metabolic intermediates present in a biological specimen. Metabolome can be defined as the complete complement of all small molecule (<1500 Da) metabolites found in a specific cell, organ or organism. Together these four ‘omes’ constitute the building blocks of systems biology (Wishar et al.
Compared to medications you cant drink alcohol with discount 25 mg meclizine with mastercard humans symptoms lung cancer purchase meclizine 25 mg line, folate deficiency is less likely to medications in checked baggage cheap 25mg meclizine amex occur in livestock animals due to symptoms e coli purchase 25 mg meclizine free shipping the greater contribution of folate from microbial synthesis in the foregut of ruminants and hindgut of non-ruminants symptoms of the flu purchase meclizine 25mg overnight delivery. However, folate deficiency has been experimentally induced in laboratory animals such as mice and rats (Bills et al. To experimentally produce folate deficiency in animals, folate-free diets have been fed in combination with sulfonamides and folate antagonists (McDowell, 2000). In animals, folate deficiency has been associated with megaloblastic anemia, leukocytopenia, poor growth, increased susceptibility to disease, dermatological lesions, and alopecia (Combs, 1992a; McDowell, 2000). After 4 mo, deficiency signs including anorexia, nervousness, incoordination in the hindquarters, loss of weight and general weakness were observed, which were associated with a thiamine deficiency. Assessment of fecal folate concentrations revealed a higher concentration than that of the diet indicating microbial synthesis of folate. Because folate status was directly assessed during this study, it is unknown to what extent the low dietary intake of folate contributed to the signs of vitamin deficiency. In one case report, a 7yr old stabled gelding consuming a diet lacking fresh grass was reported to have a low hemoglobin (11. Upon admission, foals showed signs lethargy and weakness, alopecia, skin lesions, and oral ulcers. Toxicity There is generally not a high risk of toxicity associated with high oral supplemental intakes of folate because it is a water-soluble vitamin that can be excreted and not stored. However, high folate intakes have been associated with limiting the absorption of zinc (Combs, 1992a; Tamura, 1995) and it can 35 also mask the effects of B12 deficiency (Herbert and Das, 1994). There has been no investigation into the tolerable intake limit of folate in the horse. Folate status was assessed by plasma folate, red blood cell folate, plasma homocysteine, and milk folate in monthly samples. During the experimental period, folate levels in pasture followed a similar pattern to that of growth of cool season grasses with peak values occurring in April with lowest levels occurring in June. Plasma homocysteine in foals was unaffected by growth over the last 5 mo despite the high concentrations at foaling (13. Therefore, the intake of dietary folate from feed and forage offered in this study was sufficient to maintain folate status in mares and foals during 6 mo of lactation and growth, respectively. Key Words: Folate, homocysteine, mare, foal, lactation, milk 37 Introduction Lactation and growth are two nutritionally demanding periods due to the need for the body to maintain a high rate of cell turnover. Mares maintained on pasture and sampled during the first mo of lactation were reported to have moderately low concentrations of serum folate in one study (Seckington et al. Neither of these reports assessed folate status over the duration of lactation, nor did they assess the folate status of the foal. Specifically, adequate milk folate concentrations are necessary to support early growth until the foal’s gut matures and folate requirements can be met by consumption of feed, forage, and from utilization of microbially derived folate. In order to make informed decisions regarding diet formulation and folate supplementation in horses, the effects of lactation and growth on folate status over long periods should be investigated. The objective of this study was to assess the effects of lactation and growth on folate status in Thoroughbred mares and foals in order to determine if additional dietary folate supplementation was warranted to support folate status during the two physiologically demanding periods. Mares were bred during March and April of 1999 to one of four Thoroughbred stallions located at the Center or a nearby farm. Prior to foaling, mares were paired by age, breeding date, and covering sire and randomly assigned to 2 groups of ten. Mares were maintained on adjacent bluegrass/white clover mixed pasture and were offered orchardgrass/alfalfa hay ad libitum during the winter mo. Mares were placed in foaling stalls the day of foaling and were returned to pasture with foals within 1 wk of foaling. Weaning occurred during the mo of October and November by removing two to four mares from each treatment group/wk. Supplements were developed to be isoenergetic and isonitrogenous so that they would differ only in the fiber and fat content. Synthetic folic acid was excluded from the vitamin premix so that the folate sources were only those contained inherently in the supplement and forage. Samples of blood and milk were collected in order to assess folate status by red blood cell and plasma folate, milk folate, and plasma homocysteine. Sampling was 39 conducted from 0800 to 1100 every mo beginning at foaling and ending at weaning when the foals were approximately 6 mo of age. Milk (13 ml) was collected manually into plastic WhirlPakfi bags, filtered through a 4 x 4 in gauze pad to remove foreign particles, and transferred to light protective polypropylene vial with sodium ascorbate (Sigma, St. For processing of red blood cells, 100 µl of whole blood was removed from blood collection tubes, transferred to 2 ml polypropylene vials (Sarstedt, Newton, North Carolina) containing 1 ml of 0. Plasma was transferred into 2 ml polypropylene vials and sodium ascorbate was added to a final concentration of 0. All biological samples were kept out of direct light to prevent photooxidation of folate and were stored at –80°C until analyzed. In order to assess dietary intake of folate, forage and feed samples were sampled. Pasture samples (1 to 2 kg wet weight) were obtained monthly by clipping forage using hand-held electric clippers with a 10. Validation of the radioimmunoassay for horse plasma was conducted by assessing recovery of known amounts of added 5-methyltetrahydrofolate (Schirks Laboratories, Jona, Switzerland) to plasma and by 40 dilution parallelism (1:1, 1:2, 1:4, and 1:6) (Table 2). Further validation of the commercial kit revealed the highest yield of folate could be obtained by diluting the samples to a dilution of 1:50 with distilled water prior to analysis. The latter step was found to increase the yield of folate mostly likely by increasing the denaturation of intracellular folate binding proteins in the erythrocyte. Highest concentrations of milk folate were obtained using a 1:30 dilution of milk prior to analysis. Use of the trienzyme treatment using fi-amylase, protease, and rat serum folate conjugase shown to be successful at increasing extraction of folate from foods (Tamura et al. Total milk folate concentration was increased only after incubation of milk with 0. Plasma homocysteine was determined using a pre-column derivatization procedure followed by reverse-phase separation and fluorescence detection using high-pressure liquid chromatography. After cooling the mixture at 4°C for 5 min, the proteins were precipitated by adding 100 µl of precipitation reagent (Trichloroacetic Acid), mixing thoroughly and then centrifuging the proteins into a pellet at 10, 000 x g for 5 min. Twenty µl of plasma was injected on to the heated (45°C) column at a flow rate of 0. The concentration of plasma homocysteine was quantified from its retention time relative to known standards, whereas peak areas were converted to concentration of plasma homocysteine by reference to the internal standard. A Tukey’s test was used to determine differences between mo for the variables tested. Relationships among mare and foal indexes of folate status and folate intake were evaluated using regression analyses (SlideWrite for Windows, v. Total folate concentration in the bluegrass/white clover mixed pasture over the course of 1 yr, including the present study is presented in Figure 2. There was no significant correlation between plasma folate concentration and pasture folate concentration. There was no significant correlation observed for foal plasma folate concentrations and pasture folate or mare’s milk folate. Plasma folate concentrations remained stable in all foals from 2 to 6 mo with a mean concentrations of 4. Discussion the objective of this study was to assess the effects of lactation and growth on folate status in Thoroughbred mares and foals up to 6 mo post-foaling. In the present study, folate status was influenced by lactation and growth in Thoroughbred mares and their foals fed pasture supplements and maintained on adequate mixed grass/legume pastures. However, folate status was not sufficiently lowered in either mares or foals to warrant folate supplementation. Plasma homocysteine was negatively correlated with dietary folate intake and plasma folate and has thus been used as a functional indicator of folate status (Lewis et al. Despite the moderate decline in plasma folate concentrations towards the end of lactation, all mares in the present study had plasma folate concentrations considered normal for humans (> 6 ng/ml) (Herbert and Das, 1994), which may be interpreted as normal for mares during lactation since neither mares or their suffered from any clinical abnormalities. Plasma folate concentrations at 1 mo of lactation were considerably higher than previous reports of serum folate sampled in recently foaled grazing mares (Seckington et al. Mares in the present study were maintained on quality 45 grass/legume pasture and fed supplements that inherently contained 1. The assessment of milk folate concentration is an essential component of folate status because it can be used to determine maternal folate needs due to mobilization of folate in milk and dietary folate intake in nursing infants. The decline in folate content in mares’ milk during the initial 3 mo of lactation may indicate that less folate is mobilized into the milk in order to maintain body stores of folate in the mare. Possible reasons why this may occur in the mare is due to the preservation of folate status in the mare for the benefit of the foal since mare’s can become pregnant within 7 to 9 d after foaling. Therefore, the increase in maternal folate stores ensures a good reproductive efficiency for future foals. In humans, mobilization of folate into milk for the purpose of maintaining folate status in the infant has precedence over maintaining 46 folate stores (Metz, 1970; O’Conner et al. Milk folate concentrations during lactation in the human have been shown to either increase (Cooperman et al. There was no significant association between the decline in milk folate and the decline in pasture folate that occurred during the same period. Studies in humans also found no association between maternal folate stores and milk folate concentrations (Smith et al. Concentrations of milk folate obtained in the present study are much higher than a previous estimate of 1. Milk folate concentrations in horse milk obtained in our study were similar to reports in human studies that analyze folate concentrations by microbial assay (Lim et al. We were unable to find increased folate concentrations due to the addition of protease or rat serum conjugase addition. The lowered folate concentration observed during the warm summer mo and cold winter mo was similar to growth patterns typical of cool season grasses with growth periods occurring in the fall and spring and dormancy occurring during the summer and fall. The lower folate content observed in the orchardgrass/alfalfa hay fed during the winter mo compared to the folate concentrations in pasture suggest that the 7 to 9 mo of storages likely resulted in a decline in folate concentrations in the hay. Homocysteine is converted to 47 methionine via methionine synthase, an enzyme that requires 5-methyltetrahydrofolate as a methyl donor and vitamin B12 as a co-factor. These are the first reported values of plasma homocysteine concentration in normal horses. By comparison, plasma homocysteine levels maintained between 5-15 µmol/l are considered normal in humans (Selhub, 1999). Plasma homocysteine has been used as a functional indicator of folate status in humans because it is negatively correlated to dietary folate intake and plasma folate (Lewis et al. The B-vitamins B6 and B12 are also important to homocysteine metabolism and when in limited amounts in the body, can cause increased plasma homocysteine concentrations (Selhub, 1999). However, after 2 mo, the plasma folate concentrations increased over concentrations obtained at foaling.
Improvement of platelet function folsis in therapy-refractory disseminated discoid lupus erythemalowing plateletpheresis in patients with myeloproliferative distosus medications zovirax discount 25mg meclizine otc. J Clin Apher 1998;13: Ticlopidineand clopidogrel-associated thrombotic thrombocy163–166 treatment 2 lung cancer buy meclizine. Therapeutic thrombocytapheresis: a review of 132 Matsumoto M symptoms jaw pain and headache purchase meclizine 25 mg without a prescription, Uemura M treatment ringworm generic 25mg meclizine with amex, Fujimura Y medications safe while breastfeeding order 25mg meclizine fast delivery. Am J patient with previous clopidogrel-induced thrombotic thromboHematol 1996;52:310–312. Egypt J topenic purpura/haemolytic uraemic syndrome associated with Immunol 2006;13:95–99. Clopidogrel-induced thromA case of early onset cyclosporine-induced hemolytic uremic botic thrombocytopenic purpura-hemolytic uremic syndrome syndrome resulting in renal graft loss. Transplantation 1999; vention of recurrent stroke in black patients: a randomized 67:539–544. A review of hemolytic uremic syndrome in Thrombotic thrombocytopenic purpura associated with ticlopipatients treated with gemcitabine therapy. Ticlopidine-associated thrombotic thrombocytopenic count—a clue to the diagnosis of haemolytic-uraemic synpurpura. Gemerative vasculopathy in a systemic sclerosis patient treated citabine-induced hemolytic uremic syndrome: a case report. Int J Clin Oncol 2007; Thrombotic thrombocytopenic purpura induced by cyclosporin 12:385–387. Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, blood cell exchange transfusion: a case report. Am J Hematol Bourgeois E, Thieblemont C, Leleu X, Hequet O, Salles G, 2005;80:246–247. Nakazawa Y, Hashikura Y, Urata K, Ikegami T, Terada M, with gemcitabine: a case report and review of literature. Is therapeutic plasma athy in kidney and simultaneous pancreas-kidney recipients: exchange indicated for patients with gemcitabine-induced heevidence of endothelin and cytokine involvement. Transplant Proc 1998;30:1512– gemcitabine in patients with metastatic breast cancer. Three cases of hemolytic uremic syndrome in ovarian cancer Thrombotic microangiopathy in blood and marrow transplant patients treated with combination gemcitabine and pegylated patients receiving tacrolimus or cyclosporine A. Cyclosporine-associated thrombotic microangiopathy in relong-term therapy with gemcitabine. Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry undergoing gemcitabine chemotherapy. Thrombotic thrombocytopenic purpura-hemolytic uretion: risk factors and response to treatment. Intern Med J 2006;36: tation-associated thrombotic microangiopathy: real progress or 465–467. Quinine-induced disseminated intravascular coaguwohl A, Holler E, Iacobelli M, Kentouche K, Lammle B, Moake lation and haemolytic-uraemic syndrome. Quinine-induced hemolytic-uremic synated microangiopathy: results of a consensus process by an Interdrome. Quinine-induced immune thrombocytopeathy after allogeneic hematopoietic stem cell transplantation. Bamichas G, Salum R, Sakellari I, Anagnostopoulos A, Fassas Quinine-induced immune thrombocytopenic purpura followed A, Sombolos K. Am J Kidney Dis 1999;33: grade 2–3 hematopoietic stem cell transplantation-associated 133–137. Drug-associated thrombotic botic thrombocytopenic purpura: a single-center experience thrombocytopenic purpura-hemolytic uremic syndrome. Transplantation-associated thrombotic microangiopathy: thrombotic microangiopathy: twenty-two years later. Posttransplant thrombotic microangiopathy: sensitivity multicenter survey and retrospective analysis of current effiof proposed new diagnostic criteria. Clinical impact in thrombotic thrombocytopenic purpura-hemolytic uremic of thrombotic microangiopathy on the outcome of patients syndrome. N Engl J Med with acute graft-versus-host disease after allogeneic hemato1991;325:398–403. Endocrinol Metab Clin North Am 1993;22:263– Comparison of plasma exchange with plasma infusion in the 277. Antibodies to von Willebrand factor-cleavapeutic plasmapheresis in a patient with hydatidiform mole. Yuceyar N, Karadeniz M, Erdogan M, Copur A, Akgun A, uximab for chronic recurring thrombotic thrombocytopenic Kumral E, Ozgen G. Thyrotoxic autoimmune encephalopathy purpura: a case report and review of the literature. Br J Haein a female patient: only partial response to typical immunomatol 2004;124:787–795. Minerva EndoSuccessful treatment of congenital thrombotic thrombocytocrinol 2008;33:213–228. J Thromb Haemost 2009;7:1703– use of plasmapheresis for rapid hormonal control in severe 1710. Intern Med J 2004;34:369–370; author tic plasmapheresis as a bridge to liver transplantation in fulmireply 370–361. Plasmapheresis in the treatment of hyperthyroidism associated with agranulocyto812. Intern Med effects of plasmapheresis on thyroid hormone and plasma drug 2003;42:967–970. From both literature and daily practice it has become clear that abdominal and pelvic pain are areas still under development. This guideline has been recognised as a cornerstone for important developments that have taken place in the past ten years. This guideline aims to expand the awareness of caregivers in the field of abdominal and pelvic pain and to assist those who treat patients with abdominal and pelvic pain in their daily practice. The guideline is a useful instrument not only for urologists, but also for gynaecologists, surgeons, physiotherapists, psychologists and pain doctors. However following guideline recommendations will not necessarily result in the best outcome. Structure and scope the panel wishes to take advantage of modern methods of delivering guideline information to clinicians dealing with these patients. In 2016, a stepped information structure was made, in alignment with stepped care protocols, using new digital information sources like websites and apps to aid this process. It was recognised that structuring a guideline on chronic pain is quite different from structuring one on another subject. In 2016, the guideline was rewritten to be centred around pain instead of being organ-centred. It is partly theoretical to show the importance of using this pain-centred approach. The biggest part, however, deals with the practical approach to diagnostics, treatment and management of patients with abdominal and pelvic pain. Two chapters were added at that time: Chapter 5 ‘Gastrointestinal aspects of chronic pelvic pain’ and Chapter 7 ‘Sexological aspects of chronic pelvic pain’. In the 2014 edition minor revisions were made in Chapter 5 ‘Gastrointestinal aspects of chronic pelvic pain’ and Chapter 8 ‘Psychological aspects of chronic pelvic pain’. For the 2015 edition the Panel critically reviewed the sub-chapter on bladder pain syndrome which is now a comprehensive part of the guideline . In 2017 a scoping search was performed covering all areas of the guideline and it was updated accordingly. Wood for their expertise, time and diligence in undertaking a review of these guidelines from a patient perspective. Classification involves three aspects of defining a condition: phenotyping, terminology and taxonomy. For example, chronic bladder pain may be associated with the presence of Hunner’s ulcers and glomerulation on cystoscopy, whereas other bladder pain conditions may have a normal appearance on cystoscopy. In the absence of well-defined mechanisms, describing the condition by its symptoms, signs and, where possible, by investigations, has been demonstrated to have clinical and research validity in many situations. When pain is the main symptom and pain as a disease process is considered the cause, the condition is often referred to as a pain syndrome a well-defined collection of symptoms, signs and investigation results associated with pain mechanisms and pain perception as the primary complaint. Terminology Terminology is the words that are used within classification, both to name the phenotype and within the definition of the phenotype. In the pain syndromes, the role of the nervous system in generating the sensations is thought to be pivotal, but the term syndrome is also comprehensive and takes into account the emotional, cognitive, behavioural, sexual and functional consequences of the chronic pain. When defining the phenotype, the terminology used in that definition must also be clear and if necessary defined. One of the most important guiding principles is that spurious terminology should be avoided. Terms that end in “itis” in particular should be avoided unless infection and or inflammation is proven and considered to be the cause of the pain . It must be appreciated that end-organ inflammation may be secondary and neurogenic in origin and not a primary cause of the pain. Other terms for the non-pain syndromes include “classical conditions”, “well-defined conditions” and “confusable diseases”. Clues to the mechanism As a result of systematic phenotypic and taxonomic classifications, similarities and differences between conditions become clear. Drawing comparisons between the phenotypes of different disorders allows one to compare disorders such as bladder and bowel pain syndromes, thus facilitating research and treatment. Guidelines for best treatment options As conditions become better defined, more specific treatment approaches can be adopted. In particular, there will be a move away from treatments based upon spurious terms. Generic treatments aimed at groups of conditions will be more commonplace and based upon research evidence. Patient needs A diagnosis, or name, for a set of symptoms can provide patients with a sense of being understood, as well as hope for relief. It may therefore help in acceptance of the problem as chronic, resolution of unfounded fears about its implications (if not life-threatening), and engagement in therapeutic endeavours, as well as in self-management. However, it may also lead to accessing information of variable quality associated with the diagnosis or name, and the possibility of generating new concerns about long-term consequences or about appropriateness of treatment. Investigations by end-organ specialists should therefore be aimed at obtaining a differential diagnosis; repeated, unnecessary investigations are detrimental in the management of chronic pain syndromes. A sub-division phenotype should only be used if there is adequate evidence to support its use. If the pain can be localised to an organ, then a more specific term, such as rectal pain syndrome, may be used.
Buy 25 mg meclizine with visa. How To Know if a Girl Likes You - 10 Signs She's Interested.